BR112014025041B8 - Composição farmacêutica - Google Patents
Composição farmacêuticaInfo
- Publication number
- BR112014025041B8 BR112014025041B8 BR112014025041A BR112014025041A BR112014025041B8 BR 112014025041 B8 BR112014025041 B8 BR 112014025041B8 BR 112014025041 A BR112014025041 A BR 112014025041A BR 112014025041 A BR112014025041 A BR 112014025041A BR 112014025041 B8 BR112014025041 B8 BR 112014025041B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- suvorexant
- optionally
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653539P | 2012-05-31 | 2012-05-31 | |
US201361787686P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/042959 WO2013181174A2 (en) | 2012-05-31 | 2013-05-29 | Solid dosage formulations of an orexin receptor antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014025041B1 BR112014025041B1 (pt) | 2019-10-22 |
BR112014025041B8 true BR112014025041B8 (pt) | 2023-04-18 |
Family
ID=49674030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014025041A BR112014025041B8 (pt) | 2012-05-31 | 2013-05-29 | Composição farmacêutica |
Country Status (10)
Country | Link |
---|---|
US (2) | US10098892B2 (pt) |
EP (1) | EP2854816B1 (pt) |
JP (1) | JP6263169B2 (pt) |
KR (1) | KR102123130B1 (pt) |
CN (2) | CN109078015A (pt) |
AU (2) | AU2013267613A1 (pt) |
BR (1) | BR112014025041B8 (pt) |
MX (1) | MX368859B (pt) |
RU (2) | RU2699358C2 (pt) |
WO (1) | WO2013181174A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015248736B2 (en) * | 2014-04-17 | 2018-11-29 | Sandoz Ag | Solid dispersion comprising an orexin receptor antagonist |
WO2015164160A1 (en) * | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
CN105377840B (zh) * | 2014-05-28 | 2017-12-22 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
EP3223803A1 (en) * | 2014-11-24 | 2017-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases |
CZ201587A3 (cs) | 2015-02-10 | 2016-08-17 | Zentiva, K.S. | Amorfní pevná forma suvorexantu s kyselinou sírovou |
WO2017001499A1 (en) | 2015-06-30 | 2017-01-05 | Hexal Ag | Liquid composition comprising suvorexant |
WO2017072264A1 (en) | 2015-10-29 | 2017-05-04 | Hexal Ag | Solid composition comprising suvorexant |
CN105886592A (zh) * | 2016-03-02 | 2016-08-24 | 昆明理工大学 | 一种基于食欲素受体1分子探针的药物活性成分筛选方法 |
US20190151304A1 (en) * | 2016-05-10 | 2019-05-23 | Inserm (Institut National De La Santé Et De La Rechercjae Médicale | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory |
US20200078303A1 (en) * | 2016-12-19 | 2020-03-12 | Druggability Technologies Ip Holdco Ltd. | Pharmaceutical formulations of suvorexant |
AU2018252153A1 (en) * | 2017-04-13 | 2019-11-07 | Jean Paul Remon | Xanthohumol-based compositions |
US11504327B1 (en) | 2019-01-21 | 2022-11-22 | Eric Morrison | Method of preparing nanoparticles by hot-melt extrusion |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3222359A (en) | 1965-12-07 | Process for preparing benzodiazepine compounds | ||
JP2003518485A (ja) | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | 向上された薬物濃度を与える医薬組成物 |
CA2448864C (en) * | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
KR100758045B1 (ko) * | 2002-02-01 | 2007-09-11 | 화이자 프로덕츠 인크. | 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법 |
CN101299993A (zh) * | 2005-11-04 | 2008-11-05 | 伊士曼化工公司 | 用于给药难溶的药学活性剂的羧烷基纤维素酯 |
JP5773560B2 (ja) * | 2006-02-09 | 2015-09-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Cetp阻害剤のポリマー製剤 |
CA2647678A1 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Diazepan orexin receptor antagonists |
PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
CN101702878B (zh) | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
EP2249808A2 (en) * | 2008-01-11 | 2010-11-17 | Cipla Limited | Solid pharmaceutical dosage form |
US7902376B2 (en) | 2008-01-23 | 2011-03-08 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates |
WO2012148553A1 (en) | 2011-03-03 | 2012-11-01 | Merck Sharp & Dohme Corp. | Process for the preparation of an orexin receptor antagonist |
US20160272627A1 (en) | 2012-11-12 | 2016-09-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of suvoroxant |
US20160168138A1 (en) | 2013-07-15 | 2016-06-16 | Dr. Reddy's Laboratories Limted | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant |
EP3102188A4 (en) | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
CN103923068B (zh) | 2014-02-13 | 2016-09-07 | 武汉珈瑜科技有限公司 | 用于制备suvorexant的化合物及其制备方法 |
AU2015248736B2 (en) | 2014-04-17 | 2018-11-29 | Sandoz Ag | Solid dispersion comprising an orexin receptor antagonist |
WO2015164160A1 (en) | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
CN105377840B (zh) | 2014-05-28 | 2017-12-22 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
-
2013
- 2013-05-29 AU AU2013267613A patent/AU2013267613A1/en not_active Abandoned
- 2013-05-29 CN CN201811196847.6A patent/CN109078015A/zh active Pending
- 2013-05-29 US US14/404,147 patent/US10098892B2/en active Active
- 2013-05-29 CN CN201380028103.2A patent/CN104321059A/zh active Pending
- 2013-05-29 JP JP2015515118A patent/JP6263169B2/ja active Active
- 2013-05-29 MX MX2014014644A patent/MX368859B/es active IP Right Grant
- 2013-05-29 BR BR112014025041A patent/BR112014025041B8/pt active IP Right Grant
- 2013-05-29 WO PCT/US2013/042959 patent/WO2013181174A2/en active Application Filing
- 2013-05-29 RU RU2014152031A patent/RU2699358C2/ru active
- 2013-05-29 EP EP13796870.7A patent/EP2854816B1/en active Active
- 2013-05-29 RU RU2019126797A patent/RU2759837C2/ru active
- 2013-05-29 KR KR1020147033238A patent/KR102123130B1/ko active IP Right Grant
-
2018
- 2018-02-22 AU AU2018201279A patent/AU2018201279B2/en active Active
- 2018-08-09 US US16/059,439 patent/US11160811B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11160811B2 (en) | 2021-11-02 |
MX368859B (es) | 2019-10-18 |
AU2018201279A1 (en) | 2018-03-15 |
CN104321059A (zh) | 2015-01-28 |
RU2699358C2 (ru) | 2019-09-05 |
JP6263169B2 (ja) | 2018-01-17 |
EP2854816A2 (en) | 2015-04-08 |
US20150190402A1 (en) | 2015-07-09 |
US20220062295A1 (en) | 2022-03-03 |
US20190038635A1 (en) | 2019-02-07 |
WO2013181174A3 (en) | 2014-01-30 |
RU2759837C2 (ru) | 2021-11-18 |
RU2014152031A (ru) | 2016-07-20 |
US10098892B2 (en) | 2018-10-16 |
RU2019126797A (ru) | 2019-10-07 |
MX2014014644A (es) | 2015-02-12 |
BR112014025041B1 (pt) | 2019-10-22 |
AU2018201279B2 (en) | 2019-11-21 |
KR20150014940A (ko) | 2015-02-09 |
EP2854816B1 (en) | 2020-07-08 |
WO2013181174A2 (en) | 2013-12-05 |
KR102123130B1 (ko) | 2020-06-15 |
EP2854816A4 (en) | 2015-10-28 |
AU2013267613A1 (en) | 2014-10-02 |
CN109078015A (zh) | 2018-12-25 |
RU2019126797A3 (pt) | 2020-02-25 |
JP2015518867A (ja) | 2015-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014025041B8 (pt) | Composição farmacêutica | |
BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
BR112016003229A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
IL235767A (en) | Preserved pyrolidines, pharmaceuticals containing them and their uses | |
DK3181128T3 (da) | Farmaceutisk nilotinib-sammensætning | |
MD4589C1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
BR112014014769A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou sal. | |
EP3016653A4 (en) | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | |
IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
BR112014009950A2 (pt) | composto dissubstituído, compostos e composição farmacêutica | |
BR112013019327A2 (pt) | composto, e, composição. | |
EA201490761A1 (ru) | R(+)-n-формилпропаргиламиноиндан | |
DK2897594T3 (da) | Farmaceutisk sammensætning | |
BR112015010797A2 (pt) | compostos aniônicos substituídos, e, composição farmacêutica | |
CL2014003283A1 (es) | Formulación farmacéutica. | |
EP2990039A4 (en) | Solid pharmaceutical composition | |
CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2455 DE 23/01/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |